Disease progression in COPD:

Similar documents
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น

Long-term outcomes following first shortterm clinically important deterioration in COPD

Controversies in Clinical Trials

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

Potential risks of ICS use

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital

Shaping a Dynamic Future in Respiratory Practice. #DFResp

What is the best way of assessing disease progression in COPD?

Preventing clinically important deterioration with single-inhaler triple therapy in COPD

ERS Investor & Analyst Event. Munich Tuesday 9 th September 2014

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)

Journal of the COPD Foundation

Dr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

Update on Asthma & COPD. Stephen C. Lazarus, M.D. Division of Pulmonary & Critical Care Medicine University of California San Francisco

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

C hronic obstructive pulmonary disease (COPD) is one of

Shaping a Dynamic Future in Respiratory Practice. #DFResp

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC

Three s Company - The role of triple therapy in chronic obstructive pulmonary

REDUCE AND PREVENT IS IT EASY?

Nuovi farmaci in sviluppo per la BPCO

Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention

Disclosures. The Montreal Protocol. The Spectrum of Obstructive Lung Disease: Asthma & COPD. The Spectrum of Obstructive Lung Disease: Asthma & COPD

Evidence Summary to support COPD formulary decision making and guideline development

Author's response to reviews

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited

The beneficial effects of ICS in COPD

Changing Landscapes in COPD New Zealand Respiratory Conference

COPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline

Chronic obstructive pulmonary disease (COPD) is characterized

Epidemiology of COPD Prof. David M. Mannino, M.D.

Chronic Obstructive Pulmonary Diseases:

Original. Showa Univ J Med Sci 30 2, , June 2018

COPD. Salah Zeineldine, MD FACP Pulmonary & Critical Care Medicine American University of Beirut Lebanese Society of Family Medicine 2012

Research Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD

The TORCH (TOwards a Revolution in COPD Health) survival study protocol

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement

Study No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/ formoterol

WHAT ARE THE PHYSIOLOGICAL DETERMINANTS OF EXPIRATORY FLOW?

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Debating the use of inhaled corticosteroids in the treatment of COPD. COPD Epidemiology. A quick patient case. Risk Factors for COPD 1,2

Evidence Summary to support COPD formulary decision making and guideline development

Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease

CDEC FINAL RECOMMENDATION

Adherence to inhaled therapy, mortality and hospital admission in COPD

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Study population The study population comprised a hypothetical cohort of poorly reversible COPD patients with a history of exacerbations.

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:

Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial

Characterisation and impact of reported and unreported exacerbations: results from ATTAIN

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire*

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

Pharmacotherapy for COPD

umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline

New Therapies for Asthma

A Systematic Review of the Efficacy and Safety of a Fixed-Dose Combination of Umeclidinium and Vilanterol for the Treatment of COPD

The physiological hallmark of chronic. Tiotropium as essential maintenance therapy in COPD. M. Decramer

To describe the impact of COPD exacerbations and the importance of the frequent exacerbator phenotype.

Longitudinal deteriorations in patient reported outcomes in patients with COPD

Patient. Device Clinician. Safety & efficacy

Treatment of COPD: the sooner the better?

Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo,

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

COPD Therapeutic Update

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized

Disease progression in young patients with COPD: rethinking the Fletcher and Peto model

This is the publisher s version. This version is defined in the NISO recommended practice RP

Treatment B: FF (400 µg) and UMEC (250 µg)/vi(100 µg) The indicated dose is the total of four inhalations via the dry powder inhaler.

Harnessing health data for patient and public benefit. Pragmatic trials. Tjeerd van Staa University of Manchester

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:

COPD Importance of Symptoma3c Control. Dr James Calvert FRCP PhD MPH Respiratory Physician North Bristol NHS Trust

Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review)

Rescue medication use as a patientreported outcome in COPD: a systematic review and regression analysis

Modern Management of COPD.

Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review)

Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center

Abstract. n engl j med 371;14 nejm.org october 2,

NEWER BRONCHODILATORS. Dr R Lakshmi Narasimhan SR Pulmonary Medicine

Biologics in Asthma: Present and Future

OFEV MEDIA BACKGROUNDER

Driessen et al. Respiratory Research (2018) 19:224 (Continued on next page)

Not available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33

COPD refers to a cluster of diseases (including. The Breathlessness, Cough, and Sputum Scale*

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

Roflumilast for the management of severe chronic obstructive pulmonary disease

Treatment choices for patients with asthma or COPD. Jo Riley Lead Nurse For Oxfordshire Respiratory Service

UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Transcription:

Disease progression in COPD: What is it? How should it be measured? Can it be modified? Professor Paul Jones MD, PhD, FERS Emeritus Professor of Respiratory Medicine; St George s, University of London Global Medical Expert; GSK* * Financial conflict of interest

FEV 1 (% of value at age 25) Disease progression as measured by FEV 1 100 Never smoked or not susceptible to smoke 75 50 Disability Smoked regularly and susceptible to its effects Stopped at 45 25 Death Stopped at 65 0 25 Age (years) 50 75 Fletcher et al, 1976.

Rate of decline of FEV 1 : the ISOLDE trial FEV 1 (litre) 1.50 1.45 1.40 1.35 1.30 76 ml Fluticasone propionate* Placebo 50 ml/year p=0.16 1.25 1.20 59 ml/year 0 3 1 2 2 4 3 6 Months * Not licensed for COPD Burge et al BMJ 2000; 320:1297

Rate of decline in FEV 1 (ml/yr) TORCH: Exacerbation rate and FEV 1 decline Exacerbations per year n=1735 n=1862 n=1306 P<0.001 37% faster 65% faster Adjusted for smoking status, gender, baseline FEV 1, region, BMI, prior exacerbations, treatment, time, time by treatment and covariate by time Celli et al AJRCCM 2008; 178: 332

Exacerbations and worsening in health status over 3 years 3.0 ANOVA p<0.0003 SGRQ slope (units/yr) 2.5 2.0 1.5 1.0 Getting worse faster 0.5 0 None in 3 years Infrequent <1.65/yr Frequent >1.65/yr Exacerbation Category Spencer et al. Eur Respir J 2004;23:1-5.

Change in steps per day over 3 years SE Daily activity is lower after 3 years with all degrees of severity Washki et al Am J Resp Crit Care Med 2015; 192: 295-30

FEV 1 and SGRQ changes FEV 1 (% predicted) SGRQ total score 52 51 50 49 50 48 46 44 48 42 47 40 46 38 45 36 44 34 43 32 42 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 Time (years) 30 0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 Time (years) SGRQ, St George s Respiratory Questionnaire Five-year study of male outpatients with stable COPD (n=137) Oga et al; Respir Med; 2007; 101; 146-153

ECLIPSE: Post-bronchodilator FEV1 rate of decline over 3-years 40 38 35 31 Normal or no decline 30 % patients 25 20 23 15 10 8 5 0 Fast decline >40ml Slow decline 20-40ml No change +/- 20ml Improvement >20ml Vestbo et al; NEJM 2011; 365:1184-92.

Half of people with COPD (as determined by FEV 1 ) do not appear to have abnormal rates of FEV 1 decline FEV 1 decline in early COPD cohort 1 TR3 = 53 ml/yr (47% of COPD population) TR4 = 27 ml/yr (53% of COPD population) At time of diagnosis no knowledge of how the patient reached this point Reference: 1.Adapted from Lange P et.al. NEJM 2015 Vol 373 : 111-122 2. supplementary appendix

Long-term trial issues

TORCH: Early study withdrawal on placebo: FEV1 rate of decline Healthy survivor issue Placebo patients with 3-years of data annual decline = 54 ml/year 2 Early withdrawal patients annual decline = 76 ml/year 2 Annual decline in last 6-months leading to withdrawal >100ml/year 1. Adapted from Vestbo J et al Clin. Respir J (2011) 5. 44-49 2. Celli B et al Am J Respir Crit Care Med (2008) 178. 332 338

Clinically Important Deterioration (CID) - Rationale

A composite approach to assess shortterm worsening in COPD Measurable deterioration Loss of lung function Occurrence of first exacerbation Deterioration in health status Naya I et al. Thorax. 2015; 70(3): A34 (S57)

Clinically Important Deteriorations (CID) in COPD Decrease of 100 ml from baseline in trough FEV 1 and/or Deterioration in SGRQ 4 units and/or Moderate/severe COPD exacerbation

Long term risk based on composite CID status (+) or (-) at 6-months (TORCH post hoc analysis): Placebo n=1524 Salmeterol n=1521 At 6 months CID+ (n=2870 [54%]) Fluticasone n=1534 FP/ SAL combination n=1533 Reason for CID+ status Exacerbation = 33% FEV 1 = 23% SGRQ = 17% 2 or more causes = 27% Naya I et al. Thorax. 2015; 70(3): A34 (S57) Naya et al; European Respiratory Society Congress 2016 (PA304)

FEV1 Mean change (95% CI) SGRQ mean change (95% CI) TORCH: 3-year outcome on FEV 1 & SGRQ based on composite CID status at 6-months FEV 1 (ml) deterioration over time SGRQ total score deterioration over time 150 6 100 Patients CID - 4 Patients CID + 50 0-40 10 60 110 160-50 -100 Patients CID + - 117 ml p<0.001 2 0-40 10 60 110 160-2 -4-6 -8 Patients CID - + 6.4 units p<0.001-150 Time after day 182 (weeks) -10 Time after day 182 (weeks) Naya I et al. Thorax. 2015; 70(3): A34 (S57), DOF: RF/CPD/0041/16

Subjects with 1 exacerbation (%) All cause death (% subjects) TORCH: 3-year risk assessments based on composite CID status at 6-months Future risk of exacerbations on treatment Future risk of all cause mortality on treatment Patients CID+ [73%] Patients CID+ [8.3%] Patients CID- [60%] CID+ patients had a 61% increased risk of an exacerbation (p<0.001) Median time to event 520 days [CID-] vs. 265 days [CID+] Patients CID- [6.6%] CID+ patients had a 41% increased risk of all-cause death (p<0.001) Time after day 182 (weeks) Time after day 182 (weeks) All treatment groups combined in TORCH. At 6-Mo. 2870 [54%] patients were CID (CID+) and 2422 [46%] were (CID-). Naya et al; European Respiratory Society Congress 2016 (PA304)

CID in short-term trials

Time to first clinically important deterioration: Relative Risk (RR) reduction RR: 43% (95% CI 31, 53; p<0.001) UMEC/VI 55/22mcg TIO 18mcg Singh et al. Int J COPD; 2016; 11; 1413 Post-hoc analysis of ZEP117115: Maleki-Yazdi M et al. Respir Med 2014; 108:1752 1760

All components of the composite endpoint were significantly better with UMEC/VI vs. tiotropium Proportion of patients (%) RR: 43% (p<0.001) Proportion of patients with a first clinically important deterioration event RR: 26% p=0.025 RR: 53% (p<0.001) RR: 47% (p=0.044) Composite Exacerbations SGRQ 4 units FEV 100 ml decline UMEC/VI 55/22mcg TIO 18mcg *RR = Relative Risk reduction Singh et al. Am J Respir Crit Care Med 2015:191; A5760 (poster presentation) Post-hoc analysis of ZEP117115: Maleki-Yazdi M et al. Respir Med 2014; 108:1752 1760

Preventing short-term worsening: comparison between dual and mono bronchodilator therapy Post hoc analysis of time to a first composite CID (A) Dual bronchodilator therapy (UMEC/VI) vs. tiotropium (B) Dual bronchodilator therapy (UMEC/VI) vs. placebo (C) Open triple therapy (ICS/LABA + UMEC) vs.ics/laba + placebo Tiotopium n=869 UMEC/VI n=878 Placebo n=280 UMEC/VI n=413 75% ICS/LABA + PBO n=818 ICS/LABA + UMEC n=819 56% 68% 41% 44% 46% HR 0.62 (0.54, 0.71) P<0.001 Singh et al ERS abstract PA1487 HR 0.37 (0.30, 0.45) P<0.001 0 50 100 150 Time to event (days) Malaki-Yazdi et al ERS abstract PA1001 HR 0.52 (0.45, 0.59) P<0.001 Singh et al ERS abstract PA1487 21

Summary All components contribute to CID worsening CID distinguishes between treatments in the short-term Short term worsening measured over 6 months may predict long-term outcome Prevention of short-term worsening looks a promising therapeutic target As a surrogate for long term trials To identify potential disease modifying treatments more quickly